\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

\n
Enhanc3D Genomics platform expands capabilities for drug development<\/h1>Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nCambridge-based Enhanc3D Genomics has unveiled an integrated suite of multi-omics solutions designed to enhance drug discovery processes. The platform, which leverages proprietary Promoter Capture Hi-C technology, enables high-resolution mapping of genomewide regulatory interactions to support more targeted therapeutic development approaches. <\/strong><\/p>\n
<\/p>\n
The company\u2019s core offering centres on patented technology that captures interactions between promoters and regulatory regions across the entire genome in a single assay. This approach allows researchers to analyse regulatory networks at unprecedented resolution, particularly valuable for understanding the role of non-coding regions in disease mechanisms.<\/p>\n
Platform components and applications<\/h4>\nThe newly launched suite comprises several key components, each addressing specific challenges in the drug development pipeline. GenLinkConnect focuses on accelerating target identification by mapping relationships between GWAS-identified SNPs and their associated genes in specific cell types, with particular emphasis on long-range interactions that may be missed by conventional analysis methods. GenLinkResponse enables detailed analysis of cellular regulatory networks, specifically examining how cells respond to therapeutic compounds at the epigenetic level. This is complemented by GenLinkProfile, which integrates 3D genomics interaction data with multi-omics assays to generate high-resolution contact maps and context-aware analyses of SNP-gene interactions.<\/p>\n<\/div><\/section>
\n
Cambridge-based Enhanc3D Genomics has unveiled an integrated suite of multi-omics solutions designed to enhance drug discovery processes. The platform, which leverages proprietary Promoter Capture Hi-C technology, enables high-resolution mapping of genomewide regulatory interactions to support more targeted therapeutic development approaches. <\/strong><\/p>\n
<\/p>\n
The company\u2019s core offering centres on patented technology that captures interactions between promoters and regulatory regions across the entire genome in a single assay. This approach allows researchers to analyse regulatory networks at unprecedented resolution, particularly valuable for understanding the role of non-coding regions in disease mechanisms.<\/p>\n
Platform components and applications<\/h4>\nThe newly launched suite comprises several key components, each addressing specific challenges in the drug development pipeline. GenLinkConnect focuses on accelerating target identification by mapping relationships between GWAS-identified SNPs and their associated genes in specific cell types, with particular emphasis on long-range interactions that may be missed by conventional analysis methods. GenLinkResponse enables detailed analysis of cellular regulatory networks, specifically examining how cells respond to therapeutic compounds at the epigenetic level. This is complemented by GenLinkProfile, which integrates 3D genomics interaction data with multi-omics assays to generate high-resolution contact maps and context-aware analyses of SNP-gene interactions.<\/p>\n<\/div><\/section>
\n
\n